Reversal of the estrogen receptor-negative phenotype in breast cancer and restoration of antiestrogen response

Jill Bayliss, Amy Hilger, Prakash Vishnu, Kathleen Diehl, Dorraya El-Ashry

Research output: Contribution to journalArticle

82 Citations (Scopus)

Abstract

Purpose: In breast cancer, the presence of estrogen receptor α (ER) denotes a better prognosis and response to antiestrogen therapy. Lack of ERα correlates with overexpression of epidermal growth factor receptor or c-erbB-2. We have shown that hyperactivation of mitogen-activated protein kinase (MAPK) directly represses ERα expression in a reversible manner. In this study, we determine if inhibition of MAPK in established ERα- breast cancer cell lines and tumors results in reexpression of ERα, and further, if reexpression of ERα in these ERα- tumors and cell lines could restore antiestrogen responses. Experimental Design: Established ERα- breast cancer cell lines, ERα - breast tumors, and tumor cell cultures obtained from ERα- tumors were used in this study. Inhibition of hyperactive MAPK was accomplished via the MAPK/ERK kinase1/2 inhibitor U0126 or via upstream inhibition with Iressa or Herceptin. Western blotting or reverse transcription-PCR for ERα was used to assess the reexpression of ERα in cells treated with U0126. Growth assays with WST-1 were done to assess restoration of antiestrogen sensitivity in these cells. Results: Inhibition of MAPK activity in ERα- breast cancer cell lines results in reexpression of ERα; upstream inhibition via targeting epidermal growth factor receptor or c-erbB-2 is equally effective. Importantly, this reexpressed ERα can now mediate an antiestrogen response in a subset of these ERα- breast cancer cell lines. Treatment of ERα- tumor specimens with MAPK inhibitors results in restoration of ERα mRNA, and similarly in epithelial cultures from ERα- tumors, MAPK inhibition restores both ERα protein and antiestrogen response. Conclusions: These data showboth the possibility of restoring ERα expression and antiestrogen responses in ERα- breast cancer and suggest that there exist ERα- breast cancer patients who would benefit from a combined MAPK inhibition/hormonal therapy.

Original languageEnglish
Pages (from-to)7029-7036
Number of pages8
JournalClinical Cancer Research
Volume13
Issue number23
DOIs
StatePublished - Dec 1 2007
Externally publishedYes

Fingerprint

Estrogen Receptor Modulators
Estrogen Receptors
Breast Neoplasms
Phenotype
Mitogen-Activated Protein Kinases
Tumor Cell Line
Epidermal Growth Factor Receptor
Cell Line
Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Reversal of the estrogen receptor-negative phenotype in breast cancer and restoration of antiestrogen response. / Bayliss, Jill; Hilger, Amy; Vishnu, Prakash; Diehl, Kathleen; El-Ashry, Dorraya.

In: Clinical Cancer Research, Vol. 13, No. 23, 01.12.2007, p. 7029-7036.

Research output: Contribution to journalArticle

Bayliss, Jill ; Hilger, Amy ; Vishnu, Prakash ; Diehl, Kathleen ; El-Ashry, Dorraya. / Reversal of the estrogen receptor-negative phenotype in breast cancer and restoration of antiestrogen response. In: Clinical Cancer Research. 2007 ; Vol. 13, No. 23. pp. 7029-7036.
@article{a4e0e30dfbc74969b6711d6e89079c15,
title = "Reversal of the estrogen receptor-negative phenotype in breast cancer and restoration of antiestrogen response",
abstract = "Purpose: In breast cancer, the presence of estrogen receptor α (ER) denotes a better prognosis and response to antiestrogen therapy. Lack of ERα correlates with overexpression of epidermal growth factor receptor or c-erbB-2. We have shown that hyperactivation of mitogen-activated protein kinase (MAPK) directly represses ERα expression in a reversible manner. In this study, we determine if inhibition of MAPK in established ERα- breast cancer cell lines and tumors results in reexpression of ERα, and further, if reexpression of ERα in these ERα- tumors and cell lines could restore antiestrogen responses. Experimental Design: Established ERα- breast cancer cell lines, ERα - breast tumors, and tumor cell cultures obtained from ERα- tumors were used in this study. Inhibition of hyperactive MAPK was accomplished via the MAPK/ERK kinase1/2 inhibitor U0126 or via upstream inhibition with Iressa or Herceptin. Western blotting or reverse transcription-PCR for ERα was used to assess the reexpression of ERα in cells treated with U0126. Growth assays with WST-1 were done to assess restoration of antiestrogen sensitivity in these cells. Results: Inhibition of MAPK activity in ERα- breast cancer cell lines results in reexpression of ERα; upstream inhibition via targeting epidermal growth factor receptor or c-erbB-2 is equally effective. Importantly, this reexpressed ERα can now mediate an antiestrogen response in a subset of these ERα- breast cancer cell lines. Treatment of ERα- tumor specimens with MAPK inhibitors results in restoration of ERα mRNA, and similarly in epithelial cultures from ERα- tumors, MAPK inhibition restores both ERα protein and antiestrogen response. Conclusions: These data showboth the possibility of restoring ERα expression and antiestrogen responses in ERα- breast cancer and suggest that there exist ERα- breast cancer patients who would benefit from a combined MAPK inhibition/hormonal therapy.",
author = "Jill Bayliss and Amy Hilger and Prakash Vishnu and Kathleen Diehl and Dorraya El-Ashry",
year = "2007",
month = "12",
day = "1",
doi = "10.1158/1078-0432.CCR-07-0587",
language = "English",
volume = "13",
pages = "7029--7036",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "23",

}

TY - JOUR

T1 - Reversal of the estrogen receptor-negative phenotype in breast cancer and restoration of antiestrogen response

AU - Bayliss, Jill

AU - Hilger, Amy

AU - Vishnu, Prakash

AU - Diehl, Kathleen

AU - El-Ashry, Dorraya

PY - 2007/12/1

Y1 - 2007/12/1

N2 - Purpose: In breast cancer, the presence of estrogen receptor α (ER) denotes a better prognosis and response to antiestrogen therapy. Lack of ERα correlates with overexpression of epidermal growth factor receptor or c-erbB-2. We have shown that hyperactivation of mitogen-activated protein kinase (MAPK) directly represses ERα expression in a reversible manner. In this study, we determine if inhibition of MAPK in established ERα- breast cancer cell lines and tumors results in reexpression of ERα, and further, if reexpression of ERα in these ERα- tumors and cell lines could restore antiestrogen responses. Experimental Design: Established ERα- breast cancer cell lines, ERα - breast tumors, and tumor cell cultures obtained from ERα- tumors were used in this study. Inhibition of hyperactive MAPK was accomplished via the MAPK/ERK kinase1/2 inhibitor U0126 or via upstream inhibition with Iressa or Herceptin. Western blotting or reverse transcription-PCR for ERα was used to assess the reexpression of ERα in cells treated with U0126. Growth assays with WST-1 were done to assess restoration of antiestrogen sensitivity in these cells. Results: Inhibition of MAPK activity in ERα- breast cancer cell lines results in reexpression of ERα; upstream inhibition via targeting epidermal growth factor receptor or c-erbB-2 is equally effective. Importantly, this reexpressed ERα can now mediate an antiestrogen response in a subset of these ERα- breast cancer cell lines. Treatment of ERα- tumor specimens with MAPK inhibitors results in restoration of ERα mRNA, and similarly in epithelial cultures from ERα- tumors, MAPK inhibition restores both ERα protein and antiestrogen response. Conclusions: These data showboth the possibility of restoring ERα expression and antiestrogen responses in ERα- breast cancer and suggest that there exist ERα- breast cancer patients who would benefit from a combined MAPK inhibition/hormonal therapy.

AB - Purpose: In breast cancer, the presence of estrogen receptor α (ER) denotes a better prognosis and response to antiestrogen therapy. Lack of ERα correlates with overexpression of epidermal growth factor receptor or c-erbB-2. We have shown that hyperactivation of mitogen-activated protein kinase (MAPK) directly represses ERα expression in a reversible manner. In this study, we determine if inhibition of MAPK in established ERα- breast cancer cell lines and tumors results in reexpression of ERα, and further, if reexpression of ERα in these ERα- tumors and cell lines could restore antiestrogen responses. Experimental Design: Established ERα- breast cancer cell lines, ERα - breast tumors, and tumor cell cultures obtained from ERα- tumors were used in this study. Inhibition of hyperactive MAPK was accomplished via the MAPK/ERK kinase1/2 inhibitor U0126 or via upstream inhibition with Iressa or Herceptin. Western blotting or reverse transcription-PCR for ERα was used to assess the reexpression of ERα in cells treated with U0126. Growth assays with WST-1 were done to assess restoration of antiestrogen sensitivity in these cells. Results: Inhibition of MAPK activity in ERα- breast cancer cell lines results in reexpression of ERα; upstream inhibition via targeting epidermal growth factor receptor or c-erbB-2 is equally effective. Importantly, this reexpressed ERα can now mediate an antiestrogen response in a subset of these ERα- breast cancer cell lines. Treatment of ERα- tumor specimens with MAPK inhibitors results in restoration of ERα mRNA, and similarly in epithelial cultures from ERα- tumors, MAPK inhibition restores both ERα protein and antiestrogen response. Conclusions: These data showboth the possibility of restoring ERα expression and antiestrogen responses in ERα- breast cancer and suggest that there exist ERα- breast cancer patients who would benefit from a combined MAPK inhibition/hormonal therapy.

UR - http://www.scopus.com/inward/record.url?scp=37249069903&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=37249069903&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-07-0587

DO - 10.1158/1078-0432.CCR-07-0587

M3 - Article

C2 - 18056179

AN - SCOPUS:37249069903

VL - 13

SP - 7029

EP - 7036

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 23

ER -